Defunct Company
Total Trials
7
As Lead Sponsor
4
As Collaborator
3
Total Enrollment
502
NCT02910219
Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients
Phase: Phase 2
Role: Collaborator
Start: Jan 31, 2017
Completion: Nov 23, 2020
NCT03898856
Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea in Non-HIV Patients
Phase: Phase 4
Start: Apr 1, 2019
Completion: Jan 30, 2025
NCT04192487
Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea
Role: Lead Sponsor
Start: Oct 22, 2019
Completion: Aug 31, 2021
NCT04538625
Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy
Phase: Phase 3
Start: Oct 7, 2020
Completion: Oct 30, 2023
NCT05226494
Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma
Phase: Phase 1
Start: Jun 23, 2022
Completion: Oct 31, 2027
NCT06326645
Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome
Phase: Early Phase 1
Start: Mar 3, 2025
Completion: Feb 1, 2026
NCT06721871
Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)
Start: May 1, 2025
Completion: Mar 31, 2026